Vibegron shows high efficacy in pediatric patients with refractory daytime urinary incontinence.
anticholinergics
neurodevelopmental disorder
overactive bladder
pediatric
urinary incontinence
β3 adrenoreceptor agonists
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
27
01
2023
received:
21
10
2022
accepted:
11
02
2023
medline:
13
4
2023
pubmed:
26
2
2023
entrez:
25
2
2023
Statut:
ppublish
Résumé
Sparse published reports exist nowadays on vibegron and pediatric overactive bladder, so its usefulness of this agent remains unclear. The purpose of this study was to clarify the effectiveness of vibegron for pediatric cases of daytime urinary incontinence (DUI), including refractory cases. Participants comprised 57 patients treated with vibegron for DUI from March 2019 to April 2022. To investigate treatment outcomes and risk factors for pediatric patients with refractory DUI, the following factors were evaluated: age at initiatial administration; frequency of DUI; duration of vibegron treatment; presence of neurodevelopmental disorders (NDDs); presence of constipation; and anticholinergic medications before and after initiation of treatment. Patients included 38 boys and 19 girls with a median age at initial administration of 111 months (range: 64-202 months) and a median administration term of 6 months (range: 1-33 months). With treatment for 6 months, the response rate (complete response + partial response) was 68.3%. A total of 24 cases with NDD showed a 72.0% response rate at 6 months. As for the relationship between anticholinergic agents and vibegron, 15 cases were treated with vibegron as the first choice without anticholinergics (First-choice cases), and 33 cases were treated with vibegron alone after switching from anticholinergics (Switch cases). Vibegron was used in combination with anticholinergic agents in 9 cases (Add-on cases). Response rates at 6 months were 85.0% in First-choice cases, 66.3% in Switch cases, and 40.7% in Add-on cases. Univariate analyses failed to identify any significant risk factors for refractory cases. Vibegron was effective in pediatric cases of DUI, with efficacy demonstrated within a short time in many cases. Vibegron is expected to play a significant role in the treatment of DUI in pediatric cases.
Substances chimiques
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
0
Pyrimidinones
0
Cholinergic Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
794-798Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of Vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316-324. doi:10.1097/JU.0000000000000807
Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective β 3-Adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 73 2018;73(5):783-790. doi:10.1016/j.eururo.2017.12.022.
Igawa Y, Aizawa N, Michel MC. β3 -adrenoceptors in the normal and diseased urinary bladder-what are the open questions? Br J Pharmacol. 2019;176(14):2525-2538. doi:10.1111/bph.14658
Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN. Efficacy of Vibegron and Mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison. Adv Ther. 2021;38(11):5452-5464. doi:10.1007/s12325-021-01902-8.
Fryer S, Nicoara C, Dobson E, et al. Effectiveness and tolerability of mirabegron in children with overactive bladder: a retrospective pilot study. J Pediatr Surg. 2020;55(2):316-318. doi:10.1016/j.jpedsurg.2019.10.044
Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society. J Urol. 2014;191(6):1863-1865. doi:10.1016/j.juro.2014.01.110
Andersson KE. On the site and mechanism of action of β3-Adrenoceptor agonists in the bladder. Int Neurourol J. 2017;21(1):6-11. doi:10.5213/inj.1734850.425
Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective pilot study of Mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70(1):9-13. doi:10.1016/j.eururo.2016.02.007
Morin F, Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Dual therapy for refractory overactive bladder in children: a prospective open-label study. J Urol. 2017;197(4):1158-1163. doi:10.1016/j.juro.2016.11.101
Kitta T, Chiba H, Kon M, et al. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. J Pediatr Urol. 2022;18:563-569. doi:10.1016/j.jpurol.2022.07.012
Kato T, Mizuno K, Nishio H, Yasui T, Hayashi Y. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report. J Med Case Rep. 2021;15:86.
Oelrich TM. The urethral sphincter muscle in the male. Am J Anat. 1980;158(2):229-246. doi:10.1002/aja.1001580211
Lu Y, Dewan PA. Congenital urethral obstruction: the video-endoscopic perspective. BJU Int. 2006;98(5):953-959. doi:10.1111/j.1464-410X.2006.06420.x
Chang SJ, Van Laecke E, Bauer SB, et al. Treatment of daytime urinary incontinence: a standardization document from the International Children's Continence Society: guideline for pediatric incontinence. Neurourol Urodyn. 2017;36(1):43-50. doi:10.1002/nau.22911
Wang J, Zhou Z, Cui Y, et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22-30. doi:10.1002/nau.23863
Crimmins CR, Rathbun SR, Husmann DA. Management of urinary incontinence and nocturnal enuresis in attention-deficit hyperactivity disorder. J Urol. 2003;170(4 Pt 1):1347-1350. doi:10.1097/01.ju.0000084669.59166.16
von Gontard A, Moritz AM, Thome-Granz S, Freitag C. Association of attention deficit and elimination disorders at school entry: a population based study. J Urol. 2011;186(5):2027-2032. doi:10.1016/j.juro.2011.07.030
Mahjani B, Koskela LR, Mahjani CG, et al. Systematic review and meta-analysis: relationships between attention-deficit/hyperactivity disorder and urinary symptoms in children. Eur Child Adolesc Psychiatry. 2022;31(4):663-670. doi:10.1007/s00787-021-01736-3
Gontard A, Hussong J, Yang SS, Chase J, Franco I, Wright A. Neurodevelopmental disorders and incontinence in children and adolescents: attention-deficit/hyperactivity disorder, autism spectrum disorder, and intellectual disability-a consensus document of the International Children's Continence Society. Neurourol Urodyn. 2022;41(1):102-114. doi:10.1002/nau.24798.